Accept most insurances. (800)W8MD-007
How can W8MD Weight Loss, Sleep & MedSpa Help?
Obesity, Sleep and Aesthetics - A-Z CONDITIONS
If you are overweight or obese, and need help losing weight, W8MD can help. Accepting most insurances, with an evidence based practice, with many locations in the US with physicians and staff experienced and well trained, W8MD has helped thousands of patients lose weight and is ready to help you. W8MD’s insurance physician weight loss program offers FDA appetite suppressants or diet pills such as PHENTERMINE (ADIPEX), QSYMIA, BELVIQ, SAXENDA, TENUATE(DIETHYLPROPION), BONTRIL (PHENDIMETRAZINE) etc. We also offer optional and delicious VLCD meal replacements for fast weight loss results. In addition to weight loss, W8MD offers state of the art Sleep Medicine, IV Therapy, and Medical Aesthetics / Spa services. Book Appointments or call (800)W8MD-007. Read success stories...
After years of rejecting many medications for weight loss despite the country having epidemic proportions of obesity, the FDA finally seems to wake to the reality. Until recently, the FDA board that reviewed weight loss medications had no single bariatrician.
Some of the medications that were denied in the past were combination medications where the constituents of the combination were already on the market but FDA managed to deny some of these medications for theoretic concerns.
About 2010, FDA finally had a medical bariatrician join its ranks to sit on the board that reviews weight loss medications. So far, we have seen two new weight loss medications approved. This is a step in the right direction and we hope that the FDA keeps pace with the growing epidemic of Obesity. Here is the information on the new drug, Belviq. Please note that it is going to take a little bit of time for the medication to be available on the market. W8MD intends to be one of the first to start using Belviq for W8Loss as soon as they become available on the market.
The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.
“Obesity threatens the overall well being of patients and is a major public health concern,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition.”
Belviq works by activating the serotonin 2C receptor in the brain. Activation of this receptor may help a person eat less and feel full after eating smaller amounts of food. The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. All participants received lifestyle modification that consisted of a reduced calorie diet and exercise counseling. Compared with placebo, treatment with Belviq for up to one year was associated with average weight loss ranging from 3 percent to 3.7 percent. About 47 percent of patients without type 2 diabetes lost at least 5 percent of their body weight compared with about 23 percent of patients treated with placebo. In people with type 2 diabetes, about 38 percent of patients treated with Belviq and 16 percent treated with placebo lost at least 5 percent of their body weight.
Belviq treatment was associated with favorable changes in glycemic control in those with type 2 diabetes. The approved labeling for Belviq recommends that the drug be discontinued in patients who fail to lose 5 percent of their body weight after 12 weeks of treatment, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment.
Belviq should not be used during pregnancy. Treatment with Belviq may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. These include, but are not limited to, drugs commonly used to treat depression and migraine.
Belviq may also cause disturbances in attention or memory. In 1997, the weight-loss drugs fenfluramine and dexfenfluramine were withdrawn from the market after evidence emerged that they caused heart valve damage. This effect is assumed to be related to activation of the serotonin 2B receptor on heart tissue. When used at the approved dose of 10 milligrams twice a day, Belviq does not appear to activate the serotonin 2B receptor.
Heart valve function was assessed by echocardiography in nearly 8,000 patients in the Belviq development program. There was no statistically significant difference in the development of FDA-defined valve abnormalities between Belviq and placebo-treated patients. Because preliminary data suggest that the number of serotonin 2B receptors may be increased in patients with congestive heart failure, Belviq should be used with caution in patients with this condition.
Belviq has not been studied in patients with serious valvular heart disease. The drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke.
The most common side effects of Belviq in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation, and in diabetic patients are low blood sugar (hypoglycemia), headache, back pain, cough, and fatigue. Belviq is manufactured by Arena Pharmaceuticals GmbH of Zofingen, Switzerland, and distributed by Eisai Inc. of Woodcliff Lake, N.J. Source: US FDA
Browse Ruwix, the portal dedicated to online puzzle programs and tutorials.
W8MD weight loss locations for Belviq that accept insurance
|W8MD'sNYC Weight Loss, Sleep and Medical Aesthetics, Brooklyn, NY.|
Prab R. Tumpati, MD - Medical Director and Founder
|2632 E 21st St Ste L2 Brooklyn NY 11235
NYC medical weight loss
|W8MD's Philadelphia, Weight Loss, Sleep and Medical Aesthetics, NE Philadelphia, PA.||1718 Welsh Road, 2nd Fl, Ste C, Philadelphia PA 19115
Philadelphia Medical Weight Loss
|W8MD's King Of Prussia, Weight Loss, Sleep and Medical Aesthetics, Wayne, PA.||987 Old Eagle School Road, Building K, Ste 712, Wayne PA 19087
|W8MD's New Jersey Weight Loss, Sleep and Medical Aesthetics, Cherry Hill, NJ.||140 E Evesham Road, Cherry Hill NJ 08003
NJ Weight Loss Center
GET UP TO 50% OFF
AVAILABLE FOR A LIMITED TIME!
W8MD’s medical aesthetic / MedSpa programs offers a wide variety of advanced skin care measures to make you look your best with younger and brighter skin. Our skin treatments include mesotherapy fat dissolve injections, oxygen super facials with microdermabrasion, IPL photofacials, microneedle skin rejuvination, PRP (Platelet Rich Plasma) therapy, non-ablative laser skin resurfacing, botox, fillers and aesthetic treatments. Learn more...
|IV Nutrition||IPL Photofractinoal
|Affordable Botox||Mesotherapy Fat Dissolve
W8MD's medical weight loss, sleep, aesthetic & IV nutrition programs
W8MD’s insurance weight loss program is unique in many ways with a comprehensive multidisciplinary approach to losing weight fast that addresses all the complex issues leading to weight gain, both in adults and children. Since its inception in 2011, W8MD has successfully helped thousands of patients lose weight successfully succeed in not only losing weight but also keep it off with an ongoing maintenance plan.
We offer FDA appetite suppressants or diet pills, such as Phentermine or Adipex, Qsymia, Belviq, Saxenda, Contrave, Bontril, Tenuate etc. We also offer very low calorie diets (VLCD),with optional and affordable insulin resistance.
Also see our other blogs